Recent research and future prospects for gemtuzumab ozogamicin: Could it make a comeback?

Expert Review of Hematology

Volumn 7, Issue 4, 2014, Pages 427-429

  O'Hear, Carol ^a,b   Rubnitz, Jeffrey E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

acute myeloid leukemia; antibody; cd33; gemtuzumab ozogamicin; pediatric oncology

Indexed keywords

GEMTUZUMAB OZOGAMICIN; AMINOGLYCOSIDE; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG TARGETING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL; HUMAN; MEDICAL RESEARCH; MINIMAL RESIDUAL DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REMISSION; REVIEW; SURVIVAL RATE; LEUKEMIA, MYELOID, ACUTE;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 84904321124     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.924849     Document Type: Review

References (18)

1. Dinndorf PA, Andrews RG, Benjamin D, et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986;67:1048-53
2. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-6
3. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854-60
4. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29:369-77
5. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379: 1508-16
6. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30:3924-31
7. Li X, Xu SN, Qin DB, et al. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia a meta-analysis of prospective randomized phase III trials. Ann Oncol 2014;25:455-61
8. Kharfan-Dabaja MA, Hamadani M, Reljic T, et al. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013;163: 315-25
9. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Childrens Oncology Group. Cancer 2012;118:761-9
10. Gamis A, Aplenc R, Alonzo TA, et al. Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk- Results From The Randomized Phase III Childrens Oncology Group (COG) Trial, AAML0531. Blood 2013;122(21):355
11. Hasle H, Abrahamsson J, Forestier E, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 2012;120: 978-84
12. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11:543-52
13. OHear C, Inaba H, Pounds S, et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 2013;119:4036-43
14. Kung Sutherland MS, Walter RB, Jeffrey SC, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013;122:1455-63
15. Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014;123: 554-61
16. Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014;123: 356-65
17. Wiernik A, Foley B, Zhang B, et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res 2013;19:3844-55
18. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014. [Epub ahead of print]